GKOS Trading Analysis - 11/20/2026 03:36 PM — TRU-SENTIMENT

GKOS (Glaukos Corporation) at $234.96. True Sentiment Bearish, delta 40-60 call 19% / put 81%, call $641,580 vs put $2,755,430. RSI 48.8.

TRU-SENTIMENT · DeltaNeutral

GKOS Trading Analysis - 11/20/2026 03:36 PM — TRU-SENTIMENT

Options chain · Stock chart · Baseline chart

GKOS (Glaukos Corporation) at $234.96. True Sentiment Bearish, delta 40-60 call 19% / put 81%, call $641,580 vs put $2,755,430. RSI 48.8.

Symbol
GKOS
Price
$234.96
Article bias (separate from True Sentiment)
bullish
Conviction
medium
Published
2026-11-20 15:36:00 ET
Author
DeltaNeutral staff

TRUE SENTIMENT ANALYSIS (DELTA 40-60 OPTIONS)

True Sentiment Analysis (Delta 40-60 Options)

Options flow (Delta 40-60 only) for 2026-11-20 shows:

Call Dollar Volume: $641,580.00 (18.9%) Put Dollar Volume: $2,755,430.00 (81.1%) Total: $3,397,010.00

Sentiment is Bearish. Put contracts 2,116 vs call 336; put trades 4 vs call 7 but put notional dominates. Pure directional positioning suggests near-term defensive or bearish conviction. Divergence: technicals bullish (MACD positive, price > SMA 20/50) but options sentiment bearish — spread recommendation engine returned no trade due to divergence.

Note: Options flow shows heavy put dollar volume at Delta 40-60 range, bearish pure conviction.

Key Statistics: GKOS

$235.74 -0.62%
52-Week Range
$93.78 - $255.19
Market Cap
$13.95B
P/E (TTM)
97.30
PEG Ratio
N/A
Beta
0.75
Next Earnings
N/A
Avg Volume
$698,681
Dividend Yield
0.00%

Fundamental Snapshot

Valuation

P/E (trailing)97.30
EPS (trailing 12 mo)$-2.94
Market cap$13.95B
Shares outstanding59.2M

Dividend

Dividend yield0.00%

Risk & range

Beta0.75
52-week low$93.78
52-week high$255.19
Historical volatility97.4%

Ownership & trading

Institutional ownership88.0%
Average daily volume1.9M sh

Reported figures; no analyst estimates.


📈 Analysis

News Headlines & Context

Glaukos Corporation (GKOS) is a medical technology company focused on surgical and therapeutic solutions for eye diseases such as glaucoma. Recent general-knowledge context for the name includes:

  • Glaukos has been expanding its iDose TR sustained-release glaucoma implant commercialization, a recurring catalyst watched by medtech investors.
  • The company reported prior-quarter revenue growth backed by international adoption, though profitability remains pressured by commercial scaling.
  • No confirmed near-term earnings date is embedded in the provided data, but fiscal year end is listed as 2025-12-01, with historical volatility elevated at 97.41%.
  • Pipeline updates or payer coverage decisions for glaucoma devices could act as significant catalysts impacting the stock.
  • Context: The embedded options sentiment is bearish even as technical indicators lean bullish, suggesting headline or positioning-driven caution not fully reflected in price trends.

Fundamental Analysis

Based strictly on the provided FUNDAMENTALS data:

MetricValue
Trailing P/E97.30
Trailing EPS-2.94
Market Cap$13,954,804,795.00
Shares Outstanding59,197,000.00
Dividend Yield0.00%
Beta0.75
52-Week High$255.19
52-Week Low$93.78
Institutional Ownership88.01%
Average Volume1,912,000.00
Historical Volatility97.41%

Revenue growth (YoY), gross/operating/net margins, ROE, Debt/Equity, and Free Cash Flow are not provided (null). Trailing EPS is negative at -2.94, and trailing P/E is elevated at 97.30, indicating the market prices in future growth despite current net losses. PEG ratio is null, so no growth-adjusted valuation comparison is available. Analyst consensus and target mean price are null. Fundamentals show high institutional ownership (88.01%) and low beta (0.75) but weak current earnings. This diverges from the bullish technical picture (price above SMA 50 and 20), where price strength is not yet supported by positive earnings.

Current Market Position

Current price per indicators is $237.21 (calculated 2026-11-20, based on 2026-11-19 close). Daily history shows 2026-11-19 close at $237.21 after opening $234.80, high $238.55, low $231.61, volume 517,201. Minute bars for 2026-11-19 to 2026-11-20 show opening 2026-11-19 09:30 at $233.79 and final 2026-11-20 15:05 at $234.96, with intraday range roughly $231.61 to $238.55. Intraday momentum is flat-to-slightly-down into close (last bar close $234.96 below prior $235.79).

Support (daily low 11-19)
$231.61
Resistance (daily high 11-19)
$238.55
Bollinger Lower
$178.04
Bollinger Upper
$276.36
30d High
$255.19

Technical Analysis

Technical Indicators

Current Price
$237.21
SMA 5
$241.09
SMA 20
$227.20
SMA 50
$189.80
RSI 14
48.79
MACD
15.47
Signal
12.38
Histogram
3.09
Boll Upper
$276.36
Boll Mid
$227.20
Boll Lower
$178.04
ATR 14
11.60

Price is above SMA 20 ($227.20) and SMA 50 ($189.80) but below SMA 5 ($241.09), showing short-term cooling within a broader uptrend. RSI 14 at 48.79 is neutral, no overbought/oversold. MACD (15.47) above signal (12.38), histogram positive (3.09) = bullish momentum. Bollinger mid $227.20, price inside upper/lower (no squeeze signal). 30-day range high $255.19, low $159.89; current $237.21 is ~62% up the range.

True Sentiment Analysis (Delta 40-60 Options)

Options flow (Delta 40-60 only) for 2026-11-20 shows:

Call Dollar Volume: $641,580.00 (18.9%) Put Dollar Volume: $2,755,430.00 (81.1%) Total: $3,397,010.00

Sentiment is Bearish. Put contracts 2,116 vs call 336; put trades 4 vs call 7 but put notional dominates. Pure directional positioning suggests near-term defensive or bearish conviction. Divergence: technicals bullish (MACD positive, price > SMA 20/50) but options sentiment bearish — spread recommendation engine returned no trade due to divergence.

Note: Options flow shows heavy put dollar volume at Delta 40-60 range, bearish pure conviction.

Key Price Levels (Observational Only)

Daily Low 11-19
$231.61
Daily High 11-19
$238.55
SMA 20
$227.20
30d High
$255.19
Bollinger Lower
$178.04

Interactive charts load with JavaScript. This text is the crawlable summary.